By John Kennedy ( December 18, 2017, 7:33 PM EST) -- A whistleblower claiming Amgen Inc. cost the government billions by falsely advertising quality of life benefits for its anemia biologic Epogen failed to actually identify anything that tricked the government into reimbursing claims for the drug, the Second Circuit said Monday, affirming a lower court's dismissal of the False Claims Act suit....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.